3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Sarcoma
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Paclitaxel
35
Bevacizumab
31
Carboplatin
29
pembrolizumab
25
Specimen Handling
20
Magnetic Resonance Spectroscopy
18
olaparib
16
Cisplatin
15
liposomal doxorubicin
13
Taxes
12
Immunoglobulin G
11
Gemcitabine
11
Disulfides
11
Topotecan
9
Nivolumab
9
Cyclophosphamide
9
Biopsy
8
fludarabine
7
Doxorubicin
7
mirvetuximab soravtansine
6
niraparib
5
Radiation
5
Oxaliplatin
5
Fulvestrant
5
Fluorouracil
5
trastuzumab deruxtecan
4
durvalumab
4
cediranib
4
Platinum
4
Megestrol Acetate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Genetic Counseling
×
Gynecologic
×
30 days
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled